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Introduction
Although the liver is the most frequent metastatic site
of extrahepatic neuroendocrine carcinoma (NEC), a
diagnosis of primary hepatic NEC is rarely made.1–3
Primary mixed NEC and hepatocellular carcinoma
(HCC) is even rarer.4–8 It can present as a collision
tumor that shows 2 histologically separate parts with-
out a transitional area or it can present as a combined
tumor in which both types of tumor intermingle with
each other and are continuous.8 We herein describe 
a unique case of combined primary NEC and HCC of
the liver within a single tumor nodule, in which the
NEC component comprised more than 99% of the
tumor area, and only a small nest of moderately dif-
ferentiated HCC was embedded within the NEC. Its
pathogenesis and prognosis are also discussed.
Case Report
A 65-year-old male patient was referred to our hos-
pital due to intermittent epigastric pain for 4 weeks,
after which a hepatic tumor was found by ultrasonog-
raphy. The patient had a 15-year history of chronic
hepatitis B and a 5-year history of diabetes mellitus.
Abdominal computed tomography revealed a lobulated
mass, 7.5cm in maximal diameter, in the right lobe, and
enlarged lymph nodes in the upper retroperitoneum.
Angiography showed a hypervascular patch over S4-8,
compatible with HCC. Upper gastrointestinal endos-
copy revealed esophageal varices and superficial gastritis.
Chest X-ray was normal.
Test for serum hepatitis B surface antigen (HBsAg)
was positive, while test for hepatitis C antibody (anti-
HCV) was negative. Laboratory data including white
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blood cell count, hemoglobin, hematocrit, platelet
count, aspartate aminotransferase, alanine aminotrans-
ferase, alkaline phosphatase, albumin, total bilirubin,
direct bilirubin, electrolytes and renal function test
were all within normal ranges. Plasma levels of tumor
markers, including α-fetoprotein, carcinoembryonic
antigen and CA19-9, were within normal ranges.
With suspected hepatic malignancy and regional
lymph node metastasis, the patient underwent segmen-
tal resection of the hepatic tumor and regional lymph
node dissection. The resected specimen of the liver
measured 9 × 8 × 3 cm, and there was a well-defined
and heterogeneous gray-white to brown friable tumor,
7.5 cm in diameter (Figure 1). The residual liver was
firmer than usual but without cirrhotic change.
Microscopically, the tumor consisted of predomi-
nantly small- to medium-sized neoplastic cells arranged
in solid sheets accompanied by geographic necrosis
(Figure 2A). Tumor cells were separated by dense fi-
brovascular septa and were intimately associated with
blood vessels. Tumor cells had round to oval nuclei with
inconspicuous nucleoli and scanty cytoplasm. Nuclear
molding change and mitoses were frequently seen
(Figure 2B). The morphological picture was reminis-
cent of NEC. In addition, a small island of polygonal
tumor cells with abundant eosinophilic granular cyto-
plasm and round nuclei in a trabecular structure with
variable cell thickness or pseudoglandular pattern,
consistent with moderately differentiated HCC, were
found floating in the main tumor parts (Figure 2C).
The HCC component measured about 5 × 2 mm and
made up less than 1% of the whole tumor volume. The
majority of the HCC was separated from the NEC by
a thin fibrous capsule, but there was a small focus of
HCC transition into the NEC with breakthrough of the
fibrous capsule of the HCC (Figure 2D). The residual
liver tissue revealed chronic hepatitis without cirrhotic
change.
Immunohistochemically, the small round cells
were strongly positive for neuron-specific enolase and
CD56, and focally positive for chromogranin-A and
synaptophysin. Hepatocyte-specific antigen antibody
(OCH1E5), α-fetoprotein, TTF-1, CDX2, and leu-
kocyte common antigen were negative. The immuno-
histochemical findings supported a diagnosis of NEC.
Tumor cells of the HCC were diffusely positive for
OCH1E5 and focally positive for CD56 (Figure 3).
Immunostaining for p53 protein expression and Ki-
67 proliferative index were significantly higher in the
NEC than in the HCC.
Study of the lymph nodes revealed metastatic NEC
without an HCC component. Thus, a diagnosis of pri-
mary combined NEC and HCC with regional lymph
node metastasis of NEC was made. Three months after
the operation, follow-up abdominal CT showed mul-
tiple recurrent tumors, measuring up to 16.5 × 13 ×
8 cm in diameter, in both lobes of the liver, with dif-
fuse portal vein thrombosis accompanied by metastasis
reaching bilateral adrenal glands and para-aortic lymph
nodes. The patient died 1 year after operation.
Discussion
There are 2 types of primary mixed NEC and HCC in
the liver. It can present as a combined-type tumor in
which both NEC and HCC components intermingle
with each other and cannot be clearly separated in the
transitional area within a single tumor nodule.7 A col-
lision tumor, less frequent than the combined type,
shows 2 grossly separated tumor nodules composed of
histologically different tumors.4,8 Immunohistochem-
ically, some tumor cells of the HCC in the combined
tumor may be immunoreactive for neuroendocrine
markers;7 however, the HCC component of the colli-
sion tumor revealed no neuroendocrine features. In this
patient, only a small HCC component floated within the
NEC component. Most of the HCC component was
separated by a thin fibrous capsule, but there was focal
transition into the NEC. The HCC was focally immuno-
reactive for the neuroendocrine marker CD56. There-
fore, the tumor had combined primary NEC and HCC.
The origin of the neuroendocrine components of
mixed NEC and HCC is still controversial. Two hypo-
theses have been postulated: (1) malignant transforma-
tion of hepatic stem cells;2,5 and (2) neuroendocrine
differentiation of HCC cells under certain circum-
stances.4,7 In our case, the second theory is favored
because the HCC component were focally positive
for the neuroendocrine marker CD56. Therefore, if 
a poorly-developed tumor clone of HCC underwent
Figure 1. Resected liver specimen shows a well-defined tumor
with heterogeneous gray-white and brown cut surface.
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neuroendocrine differentiation and was transformed
into an NEC, it is possible that the original HCC was
completely replaced by the NEC.4 Yamaguchi et al7 also
found the expression of p53 protein and Ki-67 prolif-
erative index to be significantly higher in the NEC
component than in the HCC component. This finding
further confirms that NEC has higher proliferative
activity and malignant potential than ordinary HCC.
Based on the 3 features observed in our patient—
the HCC component comprised less than 1% of the
whole tumor, p53 protein expression and Ki-67 pro-
liferative index were higher in the NEC than in the
HCC, and HCC focally transitioned into the NEC with
breakthrough of the fibrous capsule of the HCC—we
can speculate that a poorly differentiated part of the
HCC underwent neuroendocrine differentiation, pro-
liferated and transformed into an NEC.4 Because of
its highly proliferative activity and malignant potential,
it gradually replaced the original HCC component.
The tumor was now at the end stage of the transitional
Figure 2. (A) The neoplastic cells of the neuroendocrine carcinoma (NEC) are arranged in a solid pattern accompanying geographic
necrosis (hematoxylin & eosin [H&E]; original magnification, 40×). (B) Tumor cells of the NEC have round to oval molded nuclei with
scanty cytoplasm and frequent mitoses (H&E; original magnification, 400×). (C) Moderately differentiated hepatocellular carcinoma
(HCC) is predominantly separated from NEC by a thin fibrous capsule (H&E; original magnification, 40×). (D) Focal transitional area
between HCC and NEC is observed (H&E; original magnification, 200×).
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period from HCC to NEC. Thus, it is reasonable that
we only found a residual disappearing HCC compo-
nent. Thus, we believe, in the long run, it would have
transformed into a complete NEC.
Most patients with primary hepatic NEC die within
1 year with or without tumor resection,4 whereas the
actuarial 1- and 5-year survival rates are 67% and 18%,
respectively, after partial hepatectomy for patients with
HCC.9 The prognoses for combined- or collision-type
NEC and HCC are uncertain due to the few reported
cases. However, p53 protein expression and Ki-67 pro-
liferative index were higher in the NEC component
than in the HCC component, and the metastatic tu-
mors always consist of NEC only. We believe that pri-
mary mixed NEC and HCC run aggressively, with
behavior similar to that of primary hepatic NEC rather
than conventional HCC.
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Figure 3. (A) Hepatocellular carcinoma (HCC) is strongly positive for hepatocyte-specific antigen, while neuroendocrine carcinoma (NEC)
is nonreactive for hepatocyte-specific antigen (original magnification, 100×). (B) HCC is negative for synaptophysin, but NEC is
immunoreactive for synaptophysin (original magnification, 100×).
